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ABSTRACT
Objectives: To describe the presenting symptoms of
SLE in primary care using the Clinical Practice
Research Database (CPRD) and to calculate the time
from symptom presentation to SLE diagnosis.
Methods: Incident cases of SLE were identified from
the CPRD between 2000 and 2012. Presenting
symptoms were identified from the medical records of
cases in the 5 years before diagnosis and grouped
using the British Isles Lupus Activity Group (BILAG)
symptom domains. The time from the accumulation of
one, two and three BILAG domains to SLE diagnosis
was investigated, stratified by age at diagnosis
(<30, 30–49 and ≥50 years).
Results: We identified 1426 incident cases (170 males
and 1256 females) of SLE. The most frequently
recorded symptoms and signs prior to diagnosis were
musculoskeletal, mucocutaneous and neurological. The
median time from first musculoskeletal symptom to
SLE diagnosis was 26.4 months (IQR 9.3–43.6). There
was a significant difference in the time to diagnosis
(log rank p<0.01) when stratified by age and disease
severity at baseline, with younger patients <30 years
and those with severe disease having the shortest
times and patients aged ≥50 years and those with mild
disease having the longest (6.4 years (IQR 5.8–6.8)).
Conclusions: The time from symptom onset to SLE
diagnosis is long, especially in older patients. SLE
should be considered in patients presenting with flaring
or chronic musculoskeletal, mucocutaneous and
neurological symptoms.
INTRODUCTION
The time from symptom onset to diagnosis of
SLE has been reported to be approximately
2 years1–3 and increasing awareness of SLE has
reduced this time from symptom report to a
physician to diagnosis over the past 30 years.2 It
has been reported that children, males and
patients with late-onset SLE (over the age of
50) have a longer time from ﬁrst symptom to
diagnosis than adult-onset SLE,1–3 possibly due
to the higher diagnostic suspicion of SLE in
women of reproductive age.3 There is evidence
to suggest that damage can occur during the
early years of the disease and that this is related
to age at diagnosis and disease duration4 and
that a decrease in diagnostic delay contributes
to improved survival and quality of life.2
In the majority of patients, constitutional
(especially fatigue), cutaneous and musculo-
skeletal symptoms are the ﬁrst manifestations
of SLE.5–10 Children tend to have a more
severe onset of symptoms11–13 with haemato-
logical, neurological and renal involvement
occurring more commonly than in
adult-onset SLE.7 Patients with late-onset SLE
(≥50 years) tend to have a more insidious
onset of disease with severe manifestations
being infrequent;14–18 however, they are also
more likely to have greater damage at diagno-
sis, a higher frequency of comorbidities and a
higher risk of premature mortality than those
with an earlier onset of SLE.9 18–21
To date, studies reporting time from
symptom onset to diagnosis of SLE have
been conducted in specialist secondary care
settings using patient interviews or medical
record review. Accurate recall of the timing
of symptom onset will depend on how long
ago the symptoms manifested and whether
or not patients attribute speciﬁc symptoms to
their eventual diagnosis. There have been no
studies reporting on the prospective evolu-
tion of symptoms of SLE using data collected
in primary care. The aim of the study was to
describe the presenting symptoms and signs
leading up to a diagnosis of SLE, using data
prospectively collected in primary care and
to calculate the time from the ﬁrst record of
joint or skin symptoms in the 5 years before
diagnosis to SLE diagnosis, stratiﬁed by age,
sex and disease severity at diagnosis.
METHODS
Data source
The Clinical Practice Research Datalink
(CPRD, formerly the General Practice Research
Database (GPRD)) is, to our knowledge, the
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world’s largest database of longitudinal primary care
records. It contains the anonymised primary care records
for approximately 8.4% of the UK population of which it is
generally representative in terms of age and sex structure.22
Patients enter the CPRD on the latest of (a) their date of
birth, (b) the date that they register with their general prac-
titioner (GP) or (c) the date on which their GP practice
starts to contribute data to the CPRD. This is their ‘left cen-
soring’ date. They leave the CPRD on the earliest of (a)
their date of death, (b) the date they leave their GP practice
or (c) the date that their GP stops contributing data to the
CPRD. This is their ‘right censoring’ date. Diagnoses are
entered using Read codes, prescription data are generated
when GPs issue prescriptions via their ofﬁce computer.
Laboratory test data are available but for the majority of the
study period were limited to tests conducted in primary
care. The CPRD has been previously used to describe the
epidemiology of SLE in the UK.23–27
Case identification
The study period ran from 1 January 2000 to 31
December 2012. The study population included all per-
manently registered patients contributing research
standard data to the CPRD during the study period.
There were no age restrictions to the study population.
We searched the study population using Read codes for
SLE and lupus erythematosus (LE) to identify incident
cases of SLE. Incident cases of SLE were deﬁned as
those with a ﬁrst diagnosis of SLE or LE between 1
January 2000 and 31 January 2012 and who had at least
2 years of data between their left censoring date and
ﬁrst date of SLE diagnosis. We excluded patients who
had Read codes for drug-induced and those with Read
codes indicating isolated cutaneous lupus. The date of
SLE diagnosis was deﬁned as the earliest of: (a) the ﬁrst
record of SLE diagnosis or (b) the ﬁrst record of a pre-
scription for an immunosuppressant or hydroxychloro-
quine without an alternative explanatory diagnosis.
SLE is usually classiﬁed, for the purposes of research,
using the American College of Rheumatology (ACR)
classiﬁcation criteria for SLE.28 29 The CPRD is a
primary care database and data are entered by GPs for
the purposes of the clinical management of their
patients, not speciﬁcally for research. This means that
many of ACR criteria would not be routinely recorded
on the CPRD. For this reason, we searched for support-
ing evidence of SLE diagnosis in order to classify
patients with a diagnostic code for SLE as cases of SLE
and to thereby exclude patients with a diagnosis of LE
who were more likely to have only cutaneous lupus than
SLE. Figure 1 shows the algorithm for the identiﬁcation
of cases of SLE that was based on our previous study of
the epidemiology of SLE using the GPRD.23–25
Coding of presenting symptoms and signs of SLE
The medical record of each patient was searched for all
Read coded diagnoses within the British Isles Lupus
Activity Group (BILAG) domains30 that might have been
associated with the onset of SLE in the 5 years before SLE
diagnosis or to the patient’s left censoring date, which-
ever was the earliest. Figure 2 shows the timelines for
coding symptoms of SLE taking into account data censor-
ing in the CPRD. Read code lists were developed by ALN,
reviewed by a consultant rheumatologist (NMcH) and
grouped according to the BILAG domains. In order to
further investigate the proportion of patients with renal
disease presenting before diagnosis, we split the BILAG
renal domain into renal disease and treated hyperten-
sion. Treated hypertension was deﬁned as (a) a diagnosis
of hypertension plus at least one prescription for any anti-
hypertensive medicine after diagnosis of hypertension or
(b) the presence of any record of a hypertensive blood
pressure reading plus at least one prescription for any
antihypertensive medicine after the reading.
Coding of disease severity at diagnosis
We classiﬁed patients as having mild-to-moderate or
severe disease using prescribing data within the ﬁrst
12 months after diagnosis. This method of classiﬁcation
was based on the ACR and European League Against
Rheumatism treatment guidelines.31 32 Patients with at
least one prescription for an immunosuppressant or oral
prednisolone at doses >7.5 mg/day for at least 30 days
were classiﬁed as having severe disease at baseline. All
other patients were classiﬁed as having mild-to-moderate
disease. The case identiﬁcation algorithm and coding of
disease severity at diagnosis was based primarily on pre-
scribing that is recorded in the CPRD. In the UK, the
vast majority of prescribing that is hospital initiated is
continued by GPs after the initial prescription and this
continues under the guidance of the hospital specialists.
While the ﬁrst prescription for medicines, especially
immunosuppressants, is initiated in a hospital setting,
under shared-care arrangements, ongoing prescribing is
generally the responsibility of the GP with the exception
of biologics.33 34 Shared-care arrangements in the UK
ensure that there is a true transfer of information
between secondary and primary care clinicians, there-
fore, the CPRD represents an almost complete record of
prescribing for the majority of patients. It is rare that
patients are prescribed biologics as a ﬁrst-line therapy
for SLE in the UK, therefore, prescribing that is
recorded on the CPRD within the ﬁrst 12 months after
diagnosis should be reﬂective of disease severity at time
of diagnosis.
Statistical analyses
The proportion of patients with a current or historic
record of any of the signs or symptoms within each
BILAG domain30 was calculated for each 12-month
period prior to diagnosis. The proportion of patients
consulting their GP for any reason was calculated for
each 12-month period prior to diagnosis. The denomin-
ator for each period was the number of SLE cases con-
tributing data to the CPRD during that period taking
left truncation of data into account.
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Kaplan-Meier failure curves were constructed from the
date of each patient’s ﬁrst record of a musculoskeletal
symptom and of a mucocutaneous symptom in the
5 years before diagnosis to date of SLE diagnosis strati-
ﬁed by age, sex and disease severity at baseline and
taking left data truncation into account. Log rank tests
were used to test the equality of the failure functions.
The median time from ﬁrst musculoskeletal symptom
and ﬁrst mucocutaneous symptom SLE diagnosis was cal-
culated using the failure data and stratiﬁed by severity of
disease at baseline and 10-year age groups.
Ethical approval
Ethical approval for the study was granted by the
Independent Scientiﬁc Advisory Committee to the
CPRD, protocol number 13_051.
RESULTS
The study population consisted of 9 651 514 eligible
patients. There were 2303 patients with a ﬁrst record of
SLE diagnosis during the study period. Of these, 86 had
an alternative diagnosis after their SLE diagnosis and
295 were not incident cases when their prescribing was
taken into account and were therefore excluded. Of the
remaining 1922 cases, 496 did not fulﬁl the inclusion cri-
teria. Therefore, we included 1426 incident cases of SLE
in the study (170 males (11.9%) and 1256 females
(88.1%)); 1070 (75.0%) were classiﬁed as having
mild-to-moderate disease at baseline and 356 (25.0%)
were classiﬁed as having severe disease at baseline. As
expected, very few patients (n=84, 5.9%) could be classi-
ﬁed retrospectively as fulﬁlling four or more of the ACR
criteria for SLE28 29 and this was largely affected by a
lack of comprehensive test data in the patient record.
For example, there were 941 patients who had at least
one ANA test in their CPRD record with a total of 6437
ANA tests recorded at any time before or after SLE diag-
nosis. Of these, 5596 tests (86.9%) did not have a test
result recorded, 708 (11%) were recorded as ‘positive’,
‘high’ or ‘abnormal’ and 133 (2.0%) were recorded as
‘negative’ or ‘normal’.
The sex-speciﬁc incidence rates of SLE in the CPRD
population during the study period were 0.7/100 000/
Figure 1 Algorithm for the
identification of patients with a
diagnostic code for SLE. *Without
an alternative explanatory
diagnosis. †ACR criteria.28 29
‡SLICC criteria.43 CREST, limited
cutaneous systemic sclerosis;
LE, lupus erythematosus; ACR,
American College of
Rheumatology; SLICC, Systemic
Lupus International Collaborating
Clinics; NSAID, non-steroidal
anti-inflammatory drugs.
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year (95% CI 0.6 to 0.9) in males and 5.4/100 000/year
(95% CI 5.1 to 5.8) in females. The mean age at SLE
diagnosis was 49.4 years (SD 18.9, range 3–84 years) in
the males and 47.7 years (SD 17.2, range 5–91 years) in
the females. The mean duration of data contribution to
the CPRD by patients prior to SLE diagnosis was
8.6 years (SD 4.8) and 1023 patients (71.7%) had at
least 5 years of data prior to SLE diagnosis. Table 1
shows the characteristics of the included cases stratiﬁed
by disease severity at diagnosis. Ethnicity was recorded in
658 of the cases (46.1%) and the majority of these were
White (n=589, 89.5%).
The proportion (%) of patients with a record of GP
consultation for symptoms or signs within each BILAG30
domain during each time period before SLE diagnosis is
shown in ﬁgure 3. The largest increases were in consulta-
tions for symptoms within the musculoskeletal, mucocu-
taneous and general domains. The proportion of
patients having symptoms, signs or diagnoses in multiple
domains also increased in the 5 years leading up to SLE
diagnosis. The proportion of patients with three or
more domains in their record increased from 18.7%
(n=146) 5 years before diagnosis to 22.6% (n=205)
4 years before diagnosis, 321% (n=321) 3 years before
diagnosis, 24.2% (n=231) 2 years before diagnosis and
to 39.7% (n=458) in the year before SLE diagnosis. The
median number of GP consultations for any reason
increased in the 5 years before diagnosis from 1 (IQR 0–
17) 54–48 months before diagnosis to 23 (IQR 11–43) in
the 24–12 months before diagnosis and 38 (IQR 23–61)
in the 0–12 months before diagnosis.
Within each BILAG domain, the most frequently
recorded diagnoses were fatigue and malaise in 239
(16.8%). In the mucocutaneous domain, 43 patients
had a record of a maculopapular eruption and 59 had a
record of discoid rash with 426 patients (29.9%) having
a record of ‘rash’ without any further details in the
coded record. Symptoms in the musculoskeletal domain
were the most commonly recorded in the 5 years before
SLE diagnosis with a record of arthritis or arthralgia
(n=836, 58.6%) and myalgia (n=126, 8.8%). Depression
was the most commonly recorded diagnosis in the
Figure 2 Timelines used to identify symptoms recorded in the 5 years before SLE diagnosis taking into account data censoring.
Patient A. Joins the Clinical Practice Research Database (CPRD) in 1995 (their left censoring date (LCENS—the blue arrow) and
is diagnosed with SLE in 2000 (the red arrow). We require at least 2 years between their LCENS date and their date of SLE
diagnosis to include them as an incident case of SLE (the pink box). We code symptoms of SLE in the 5 years before SLE
diagnosis (the green box) and we can use all of those 5 years since their LCENS date is in 1995. Patient B. Joins the CPRD in
2004 (their LCENS date) therefore, we cannot see their medical records before 2004 (the grey box). They have at least 2 years
of data between their LCENS (2004) and date of SLE diagnosis (2012). We can only use the 4 years of data between their date
of SLE diagnosis and LCENS date to look for symptoms of SLE. Patient C. Joins the CPRD in 1998 (their LCENS date). They
have their diagnosis of SLE in 2012. For this patient, we have 14 years of research standard data (between their LCENS and
date of diagnosis). Therefore, they are an incident case of SLE as they have at least 2 years of data before their SLE diagnosis.
We can use symptoms recorded in the 5 years before diagnosis to investigate the onset of SLE. Although we have much more
data, we decided not to use data more than 5 years before diagnosis because the data became very unstable due to low
numbers. Patient D. Joins the CPRD in 2001 (LCENS date) and has their date of SLE diagnosis in 2002. They do not have
2 years of research standard data in their record between their LCENS date and date of SLE diagnosis and therefore would have
been excluded from the study because we do not have sufficient data to ascertain whether the patient is an incident or prevalent
case of SLE.
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Table 1 Characteristics of included incident cases of SLE, identified from the CPRD between 1 January 2000 and 31
December 2012, stratified by disease severity at diagnosis
Disease severity at diagnosis
Mild-to-moderate
(n=1070) Severe (n=356) All (n=1426)
Patient characteristics
Males, n (%) 932 (74.2) 324 (25.8) 1256 (88.1)
Females, n (%) 105 (61.8) 65 (38.2) 170 (11.9)
Mean age at SLE diagnosis (years, SD) 48.3 (17.0) 46.6 (18.7) 47.9 (17.4)
Age at diagnosis, n (%)
0–9 years 5 (0.5) 2 (0.6) 7 (0.5)
10–19 years 45 (4.2) 40 (11.2) 85 (6.0)
20–29 years 92 (8.6) 28 (7.9) 120 (8.4)
30–39 years 190 (17.8) 60 (16.9) 250 (17.5)
40–49 years 251 (23.5) 58 (16.3) 309 (21.7)
50–59 years 200 (18.7) 70 (19.7) 270 (18.9)
60–69 years 144 (13.5) 51 (14.3) 195 (13.7)
70–79 years 116 (10.8) 42 (11.8) 158 (11.1)
≥80 years 27 (2.5) 5 (1.4) 32 (2.2)
Supporting evidence of SLE diagnosis, n (%)
Evidence of hospital treatment for SLE 624 (58.3) 231 (64.9) 855 (60.0)
Antimalarial prescribing after diagnosis 790 (72.5) 242 (68.0) 1032 (72.4)
Oral prednisolone (minimum 3 months) after diagnosis 257 (24.0) 318 (89.3) 575 (40.3)
Immunosuppressant prescribing after diagnosis 127 (11.9) 227 (63.8) 354 (24.8)
NSAID prescribing (minimum three prescriptions) 609 (56.9) 177 (49.7) 786 (55.1)
Therapy for refractory cutaneous LE after diagnosis 63 (5.9) 20 (5.6) 83 (5.8)
Evidence of severe systemic involvement at any time after diagnosis 13 (1.2) 22 (6.2) 35 (2.5)
Four or more ACR criteria28 29 56 (5.2) 28 (7.9) 84 (5.9)
Four or more SLICC criteria43 73 (6.8) 43 (12.1) 116 (8.1)
Disease severity at baseline is defined as severe if the patient had at least one prescription for an immunosuppressant or a prescription for at
least 30 days of treatment with oral prednisolone at a dose of 7.5 mg/day or more within 12 months of date of SLE diagnosis. All remaining
patients were classified as having mild-to-moderate disease.
ACR, American College of Rheumatology; CPRD, Clinical Practice Research Database; LE, lupus erythematosus; NSAID, non-steroidal
anti-inflammatory drugs; SLICC, Systemic Lupus International Collaborating Clinics.
Figure 3 Proportion of patients
consulting their general
practitioner for symptoms within
each British Isles Lupus Activity
Group (BILAG) domain in the
5 years before SLE diagnosis
(date of diagnosis between 1
January 2000 and 31 December
2012) by months before SLE
diagnosis taking left data
truncation into account in the
denominator calculations for the
25–36, 37–48 and 49–60 months
before diagnosis.
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neurological domain (n=295, 20.6%). Very few patients
had a record of psychosis (n=6, 0.04%)) or seizures
(n=44, 3.1%)) in the 5 years before diagnosis. In the car-
diorespiratory domain, chest pain (n=284, 19.9%) and
dysponea (n=238, 16.7%) were the most commonly
recorded diagnoses. One hundred and six patients
(7.4%) had a record of serositis before SLE diagnosis.
Within the vasculitis domain, the most commonly
recorded symptoms or signs were thromboembolism
(n=97, 6.8%) and Raynaud’s phenomenon (n=81,
5.7%). The majority of patients with symptoms or signs
within the renal domain had a record of treated hyper-
tension (n=482, 33.8%), in the 5 years before diagnosis.
Only 61 patients (4.3%) had a record of nephritis, pro-
teinuria or cellular casts.
We investigated whether there were any speciﬁc com-
binations of symptoms before SLE diagnosis by tabulat-
ing frequencies of symptom combinations in the study
population but no speciﬁc pattern of symptom combina-
tions could be identiﬁed. Musculoskeletal or mucocuta-
neous symptoms or signs were recorded in 884 (62.0%)
and 585 (41.0%), respectively, of patients in the 5 years
before SLE diagnosis, therefore we constructed
Kaplan-Meier failure curves from date of ﬁrst musculo-
skeletal symptom and ﬁrst mucocutaneous symptom
record in the 5 years before date of diagnosis to SLE
diagnosis stratiﬁed by a combination of age at SLE
diagnosis (<30, 30–50 and >50 years) and baseline
disease severity (mild-to-moderate or severe) (ﬁgure 4).
There was signiﬁcant inequality of the failure functions
for musculoskeletal symptoms (log rank p<0.01) but not
for mucocutaneous symptoms (log rank p=0.33).
Patients initially presenting to their GP with musculo-
skeletal symptoms who were aged 30–49 years at SLE
diagnosis and with mild disease at baseline and those
aged 50 years or over at diagnosis irrespective of disease
severity had a longer time from symptom presentation
to SLE diagnosis than younger patients and particularly
those with severe disease at diagnosis. There was no dif-
ference in the failure functions when the data were
stratiﬁed for sex either for musculoskeletal symptoms
(log rank p=0.62) or for mucocutaneous symptoms (log
rank p=0.47). Table 2 shows the median times from ﬁrst
mucocutaneous and musculoskeletal symptom in the
5 years before diagnosis to date of diagnosis, stratiﬁed by
age and baseline disease severity. In general, time from
ﬁrst musculoskeletal symptom to SLE diagnosis
increased with increasing age and was lower for those
with severe disease at baseline. There was less variation
in time from ﬁrst mucocutaneous symptom to SLE diag-
nosis when the data were stratiﬁed by age and baseline
disease severity, consistent with the log rank test result
from the Kaplan-Meier failure curves for mucocuta-
neous symptoms.
Figure 4 Kaplan-Meier failure estimate plots for the probability of diagnosis following a first record of a musculoskeletal
symptom (3a) and first mucocutaneous symptom (3b) in the 5 years before diagnosis to date of SLE diagnosis, stratified by age
at SLE diagnosis (<30, 30–49 and ≥50 years) and baseline disease severity (mild-to-moderate or severe) taking left data
truncation into account. Disease severity at baseline is defined as severe if the patient has at least one prescription for an
immunosuppressant or a prescription for at least 30 days of treatment with oral prednisolone at a dose of 7.5 mg/day or more
within 12 months of date of SLE diagnosis with all other patients classified as having mild/moderate disease at baseline.
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DISCUSSION
To our knowledge, this is the ﬁrst study of the presenta-
tion of SLE that has used prospectively collected data on
SLE symptom presentation prior to diagnosis from the
UK primary care. While studies of the presentation of
SLE conducted in specialist secondary care cohorts have
the advantage of being able to establish the timing of
symptoms that have not been reported to a patient’s GP
and determine whether symptoms and signs are likely to
be related to their eventual diagnosis of SLE, the use of
prospectively collected primary care data adds to the sec-
ondary care data in being able to describe how and
when symptoms are reported by patients to their GPs,
thereby getting a fuller picture of the complexity of the
onset of symptoms of SLE. The data within the CPRD
are collected during the course of routine clinical
primary care and, as such, can be used to study the pres-
entation of symptoms of SLE in a real-world environ-
ment. It is within this environment that the majority of
patients with SLE will initially present therefore having
an understanding of what these patients might look like
to their GPs is essential in fully understanding barriers
to diagnosis of SLE.
We found that musculoskeletal, mucocutaneous and
neurological symptoms were the most commonly
recorded symptoms prior to diagnosis and that there was
a long lag between the onset of symptoms of SLE to
diagnosis, particularly in patients with late-onset SLE
(diagnosed at age 50 or older). We did not identify any
speciﬁc symptom combinations conﬁrming the insidious
and varied nature of SLE presentation. However, we did
note that the number of domains within which symp-
toms were being recorded increased towards the date of
diagnosis suggesting that as patients become increasingly
unwell and become multisystemic they consult their GP
more frequently, leading to an eventual diagnosis of
SLE. The proportion of patients consulting for musculo-
skeletal and mucocutaneous symptoms increased sharply
in the 6 months before diagnosis with a corresponding
rise in records for immunological abnormalities as a
result of ANA testing. This suggests that GPs are mostly
likely to suspect SLE in patients with these symptoms
and that they are likely to be responsible for triggering
the diagnostic process. However, we recognise that these
are also symptoms of many, more common, disorders
and without a general population control group, it is
not possible to draw conclusions about the predictive
value of these symptoms for an eventual diagnosis of
SLE. Importantly, the presence of some symptoms that
are used for the classiﬁcation of SLE28 29 such as photo-
sensitivity, serositis, seizures, psychosis and renal disease
are very rare in primary care prior to diagnosis. The
ﬁnding that approximately a quarter of patients with
SLE were being treated for hypertension is consistent
with estimates of the general population prevalence of
hypertension in men and women aged 35–74 years.35
The mean age of diagnosis of SLE in patients contrib-
uting data to the CPRD (49.4 years) is older than previ-
ously reported,3 13 but consistent with previous studies
using the GPRD.23 26 The reason for this is not clear. It
may be as a result of delayed recording of the diagnosis
of SLE; however, this was accounted for by backdating
Table 2 Median time (months (IQR)) from first record of musculoskeletal and mucocutaneous symptom to date of SLE
diagnosis on the CPRD stratified by age at diagnosis and baseline disease severity
Mild-to-moderate disease Severe disease
Age group n (%*) Median months (IQR) n (%*) Median months (IQR)
Time from first musculoskeletal symptom to SLE diagnosis
0–9 years 1 (0.07) – 0 –
10–19 years 20 (1.4) 6.0 (2.8–27.7) 18 (1.3) 29.7 (2.3–21.3)
20–19 years 57 (4.0) 13.9 (5.1–26.5) 15 (1.1) 3.8 (1.2–20.6)
30–39 years 122 (8.6) 22.2 (7.9–39.9) 42 (2.9) 14.5 (5.7–37.8)
40–49 years 154 (10.8) 28.7 (14.6–46.0) 29 (2.0) 7.9 (3.8–29.2)
50–59 years 133 (9.3) 29.1 (17.5–16.2) 45 (3.2) 25.6 (10.6–37.3)
60–69 years 83 (5.8) 36.1 (15.8–49.6) 41 (2.9) 34.4 (14.4–45.4)
70–79 years 68 (4.8) 30.6 (16.9–49.4) 31 (2.2) 38.9 (12.7–48.0)
80+ years 21 (1.5) 33.9 (18.6–50.4) 4 (0.3) 44.3 (28.3–49.5)
Time from first mucocutaneous symptom to SLE diagnosis
0–9 years 4 (0.3) 7.8 (3.9–12.7) 1 (0.07) –
10–19 years 15 (1.1) 6.5 (1.7–26.1) 15 (1.1) 23.2 (2.9–45.4)
20–19 years 34 (2.4) 17.0 (9.5–45.1) 9 (0.6) 26.8 (3.5–43.1)
30–39 years 74 (5.2) 25.5 (10.2–41.2) 24 (1.7) 18.9 (6.4–28.2)
40–49 years 116 (8.1) 21.4 (9.9–41.7) 20 (1.4%) 14.3 (2.3–21.8)
50–59 years 65 (4.6) 13.5 (5.2–32.4) 22 (1.5) 20.9 (5.5–38.7)
60–69 years 77 (5.4) 17.5 (8.7–36.7) 20 (1.4) 23.7 (3.8–37.4)
70–79 years 53 (3.7) 23.0 (8.1–34.1) 16 (1.1) 9.7 (3.2–30.1)
80+ years 17 (1.2) 16.1 (7.2–28.6) 3 (0.2) 4.7 (2.8–41.6)
*Percentages calculated for all SLE cases (n=1426).
CPRD, Clinical Practice Research Database.
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the date of SLE diagnosis to the ﬁrst prescription for
medicines used for the treatment of SLE. In the UK, the
majority of hospitals have a shared-care agreement with
primary care where rheumatologists will retain responsi-
bility for the management of their patient but GPs are
usually responsible for issuing prescriptions under the
guidance of the rheumatologist.36 Alternatively, this may
reﬂect a higher burden of older-onset SLE in the UK
than previously recognised with a milder presenta-
tion18 19 perhaps meaning that these patients are not
enrolled into secondary or tertiary care cohorts. This
would also explain the low incidence of symptoms of
severe SLE in this population.9 12 Additionally, while eth-
nicity is not systematically recorded for all patients in the
CPRD, the majority of those with a record of their ethni-
city were White. In studies reporting the epidemiology
of SLE in different world populations, it has been noted
that age of onset tends to be older for White compared
with Black patients.37 38 Therefore, the older age at diag-
nosis of SLE in the CPRD population is likely to be
affected by ethnicity.
The ﬁnding that musculoskeletal and mucocutaneous
symptoms are the most frequently experienced ﬁrst
symptoms of SLE has been reported previously.8 9 13
These symptoms are not uncommon in the general
population, which may explain the time from symptom
report to diagnosis because unless the symptoms put
together with others are put into the context of the sus-
picion of a relatively rare condition such as SLE, further
investigations may not be pursued. However, the data
suggest that once patients become multisystemic and are
regularly presenting to their GP with symptoms that they
do then receive a diagnosis.
The time from ﬁrst symptom to diagnosis has been
estimated to be between 0.5 and approximately 4
years.3 8 9 39–41 The estimation of time from disease
onset to diagnosis has been difﬁcult to calculate in previ-
ous studies because it depends on the symptoms that the
physician and patient attribute to SLE, the time between
diagnosis and participating in a study of SLE onset and
the accuracy of recall of the timing of symptoms that
may have arisen many years previously. In this study, we
aimed to describe the evolution of symptoms of SLE in
primary care and found that symptoms of SLE were
present in the medical records of patients for many
years before their diagnosis. Ideally, we might have esti-
mated time from symptom presentation to referral
rather than SLE diagnosis, and recording of that diagno-
sis on the CPRD. However, referral is not consistently
recorded in the CPRD, making using referral as an ana-
lysis end point of limited value. It was not possible to
determine whether symptoms such as arthralgia, rash,
headache, fatigue and depression were directly attribut-
able to SLE or to other, more common, causes such as
viral illness or injury. Nevertheless, the ﬁnding that
symptoms of SLE are frequent in patients for years
before their diagnosis, especially in older patients with
SLE, should not be overlooked.
While the use of the CPRD has allowed us to investi-
gate the evolution of symptoms of SLE in the UK
primary care, these data source does have a number of
limitations. First, no validation studies on algorithms
used to identify SLE from the CPRD have been con-
ducted. Given the nature of these algorithms, however,
we would expect that it is more likely that patients at the
extremities of the disease spectrum are the most likely
to have been missed. Second, GPs contributing to the
CPRD are only required to record symptoms and diag-
noses that are clinically relevant or result in a new diag-
nosis or hospital referral rather than all symptoms that a
patient reports. This issue is further compounded by the
use of non-speciﬁc Read codes such as those for ‘rash’
or ‘arthralgia’. These coding practices and missing test
data in the CPRD made it unfeasible to use the ACR
classiﬁcation criteria for SLE as an inclusion criteria to
the study population and only 5.7% of patients had sufﬁ-
cient data in their record to fulﬁl four or more of the
criteria. However, this is a limitation of data recording
rather than an issue that should negate the ﬁndings of
the study. The future potential for data linkage to the
CPRD may present opportunities to extend the current
study to further investigate whether earlier diagnosis
may be possible in the future. Additionally, with labora-
tories increasingly entering laboratory test results into
the primary care record of patients, over time the com-
pleteness of laboratory test results will increase in elec-
tronic databases such as the CPRD.
The potential for ‘ﬂagging’ software could be
explored in the future to enable GPs to more easily
identify patterns of symptoms that might be associated
with multisystem disease; however, this would be reliant
on the use of more speciﬁc Read codes within these
databases. Finally, the use of data from primary care is
only as useful as the information that is given to the
GP by the patient and the data that are then recorded
in the database. The date that symptoms are ﬁrst
reported to GPs will not equate to the date that
patients ﬁrst experienced the symptoms and it is likely
that they will have only reported symptoms to their GP
once they become problematic enough that self-
management is no longer sufﬁcient. When these data
were presented to a group of patients from a Lupus UK
support group, they unanimously reported not telling
their GP about some of their symptoms as they were
embarrassed and did not want to sound like a hypo-
chondriac; a sentiment that is echoed in the qualitative
literature on SLE diagnosis.42 Despite the limitations of
the study in this respect, the data do represent the
working clinical record for GPs in the UK and the
potential for developing ﬂagging software in the future
should be considered.
In conclusion, despite awareness campaigns, the delay
from symptom onset to SLE diagnosis is still long, espe-
cially in older-onset SLE. Musculoskeletal, mucocuta-
neous and neurological symptoms are the most frequent
early symptoms of SLE and therefore SLE should be
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considered in patients presenting frequently or chronic-
ally with these symptoms, including patients over the age
of 50 years.
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